Tango Therapeutics (TNGX) is back in focus after recent commentary highlighted expectations around upcoming pancreatic ductal adenocarcinoma data for its daraxonrasib and vopimetostat combination, which is drawing fresh investor attention to the stock.

Despite the recent excitement around upcoming data, Tango Therapeutics’ share price has pulled back, with the 1 day, 7 day and 30 day share price returns down 8.7%, 8.0% and 14.4% respectively. However, the 90 day share price return of 19.3% and very large 1 year total shareholder return suggest momentum has largely built over a longer horizon.

If you are looking beyond Tango to see where else sentiment is building in healthcare, this could be a good moment to scan for 39 healthcare AI stocks

With Tango’s share price cooling after a very large 1 year run and analysts setting higher price targets than the current US$20.22 level, investors now have to ask: is this a fresh entry point, or is future growth already priced in?

Preferred Price-to-Book Multiple of 7.5x: Is it justified?

Tango Therapeutics trades on a P/B of 7.5x, which sits well above both its biotech industry and peer group benchmarks at the current $20.22 share price.

P/B compares the market value of the company to its book value. A higher ratio often means investors are paying a larger premium over the net assets on the balance sheet. For early stage biotech companies that are still loss making, P/B is often used as a rough gauge of how much the market is willing to pay for the pipeline and future potential rather than current earnings.

In Tango’s case, the stock is described as expensive on this metric versus two key reference points. The US biotech industry average P/B is 2.5x and the peer average is 3.8x, so Tango’s 7.5x ratio is roughly three times the broader industry level and almost double the peer group. That kind of premium indicates investors are already assigning a relatively high value to the company’s precision oncology pipeline and expected revenue growth, even though the company is currently unprofitable and is forecast to remain so over the next three years.

With no fair ratio or DCF estimate available, there is limited guidance on what level the P/B could move towards if sentiment or assumptions shifted. Investors are therefore largely relying on their own view of the pipeline and forecast revenue growth to judge whether this premium is sensible.

Result: Price-to-book of 7.5x (OVERVALUED)

However, investors also need to weigh clinical trial uncertainty and ongoing losses of US$107.232 million. Any setback here could quickly challenge the current premium story.

Next Steps

With mixed sentiment around Tango’s premium valuation and clinical risk, this is a moment to act quickly and stress test your own view using 1 key reward and 3 important warning signs

Looking for more investment ideas?

If Tango has sharpened your focus on healthcare, do not stop there. Broader ideas can help you spot opportunities you might otherwise overlook.

• Spot potential turnaround stories early by scanning 24 elite penny stocks with strong financials that already have stronger financials backing their low share prices.
• Strengthen the core of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (46 results) that pair healthier balance sheets with fundamental support.
• Stay one step ahead by tracking the screener containing 22 high quality undiscovered gems before wider market attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.